Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Equities researchers at Cantor Fitzgerald reduced their FY2020 earnings estimates for shares of Catalyst Pharmaceuticals in a research report issued on Tuesday, March 24th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will earn $0.48 per share for the year, down from their prior estimate of $0.58. Cantor Fitzgerald currently has a “Overweight” rating and a $12.00 target price on the stock.
CPRX has been the subject of several other reports. ValuEngine raised Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, March 20th. BidaskClub cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Catalyst Pharmaceuticals in a report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $8.95.
CPRX opened at $3.89 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.62 and a quick ratio of 4.54. The business has a 50 day simple moving average of $4.10 and a 200-day simple moving average of $4.61. The stock has a market capitalization of $369.17 million, a P/E ratio of 13.41 and a beta of 2.28. Catalyst Pharmaceuticals has a 12 month low of $2.23 and a 12 month high of $7.67.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Monday, March 16th. The biopharmaceutical company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). The business had revenue of $30.12 million during the quarter, compared to analyst estimates of $30.00 million. Catalyst Pharmaceuticals had a net margin of 31.16% and a return on equity of 45.52%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Meeder Asset Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 91.4% in the fourth quarter. Meeder Asset Management Inc. now owns 6,492 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 3,100 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter worth $27,000. Virtu Financial LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $40,000. Sei Investments Co. purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $48,000. Finally, 9258 Wealth Management LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $50,000. 60.77% of the stock is owned by institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Article: Put Option Volume
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.